

- vs. seizure, 147, 2550–2551, 2551t
in ventricular tachycardia, 1491
- Syndrome of apparent mineralocorticoid excess (SAME; 11 β -hydroxysteroid dehydrogenase deficiency)
clinical features of, 306, 1620t, 2319
diagnosis of, 307
genetic considerations in, 306, 1620t, 2318t, 2319
pathogenesis of, 1621, 1621f
treatment of, 307
- Syndrome of inappropriate antidiuretic hormone (SIADH)
vs. cerebral salt wasting, 299
clinical characteristics of, 2280
differential diagnosis of, 301, 2281, 2282t
etiology of, 300, 300t, 2280–2281, 2281t
in HIV infection, 1259
hyponatremia in, 64e–4–5, 299–300, 2280
in lung cancer, 511
pathophysiology of, 299, 2279f, 2281
subtypes of, 299–300
treatment of, 64e–5, 302, 2281–2283, 2282f
tumor-associated, 64e–4–5, 610
- Syndrome X. *See* Metabolic syndrome
- Synkinesis, 2647
- Synovectomy, 2241–2242, 2246
- Synovial chondromatosis, 2246–2247
- Synovial effusion, 2221–2222
- Synovial fluid analysis
in calcium oxalate deposition disease, 2237, 2237f
in calcium pyrophosphate deposition disease, 2235, 2236f
interpretation of, 2223, 2224f
in rheumatoid arthritis, 2144
- Synovial sarcoma, 2247. *See also* Soft tissue sarcoma
- Synovitis
pathogenesis of, 2227, 2227f
pigmented villonodular, 2246, 2247f
- Synthetic cathinones (bath salts), 469e–3–4
- Synthetic lethality, 102e–6f, 102e–7, 103e–23
- Syntrophic relationships, 86e–5
- α -Synuclein, 172t, 444e–10, 453e–6
- Syphilis, **1132**
CNS involvement in. *See* Neurosyphilis
congenital
clinical features of, 836, 1136–1137
global considerations in, 1136
incidence of, 1133, 1136
oral manifestations of, 236, 238t, 1137
treatment of, 1139
diagnosis of
in HIV infection, 1138, 1138t
neurosyphilis, 1138, 1138t
organism identification, 1137
serologic tests, 770, 1137–1138, 1137f
endemic, 207e–2, 207e–2f, 207e–2t, 207e–3
epidemiology of, 879, 1133, 1133f
etiology of, 1132–1133
global considerations in, 1133
in HIV infection, 1259
immunity to, 1140
incidence of, 869–870, 1133f
latent, 1135
pathogenesis of, 1134
prevention of, 1138
primary
clinical features of, 1134–1135
differential diagnosis of, 1135
natural course of, 1134
skin manifestations of, 25e–4f, 76e–9f, 880t, 881, 1134, 1134f
treatment of, 1138–1139, 1139t
secondary, 1136
articular manifestations of, 836
cardiovascular manifestations of
aortic aneurysm, 1638
aortitis, 1134, 1136, 1643
AV conduction block, 1471, 1471t
epidemiology of, 1133, 1133f
hepatitis in, 1135
lymphadenopathy in, 408
natural course of, 1134
neurologic manifestations of. *See* Neurosyphilis
Neurosyphilis
ocular involvement in, 1135
oral manifestations of, 237, 238t
pharyngitis in, 231
renal involvement in, 1836t, 1849
skin manifestations of, 130t, 134, 353, 362, 1135
alopecia, 354–355, 355t
condylomata lata, 25e–5f
figurate lesions, 356, 356f
histopathology of, 1134
mucous patch, 1135
on palms and soles, 25e–5f, 76e–10f, 1135f
papulosquamous eruption, 25e–5f, 76e–10f, 1135f
vs. pityriasis rosea, 134, 347t, 349
on tongue, 25e–5f
treatment of, 1139, 1139t
tertiary
clinical features of, 238t, 1134, 1136
treatment of, 1139, 1139t
transmission of, 1133
treatment of, 1138–1140, 1139t
untreated, natural course of, 1134
- Syringomyelia, 2658, 2658f
- Syrinx cavities, 2658f
- Systematic reviews, 26
- Systemic inflammatory response syndrome (SIRS), 98e–3, 98e–4
- Systemic lupus erythematosus (SLE)
antiphospholipid syndrome and, 2133
autoantibodies in, 377e–5, 2125, 2126t, 2127t, 2131
clinical features of, 129t, 377e–5, 2127, 2129t
cardiovascular, 290e–1t, 290e–3, 2129
AV conduction block, 1471, 1471t
pericarditis, 1575, 2129, 2129t
SA node dysfunction, 1467
cutaneous, **366**, 2127–2128, 2129t
alopecia, 354, 355t
characteristics of, 129t, 134
discoid (chronic), 25e–3f, 76e–13f, 2127–2128, 2129t
distribution of, 366
malar erythema, 25e–3f, 76e–13f, 2128
panniculitis, 366
papulonodular red lesions, 366
papulosquamous lesions, 76e–13f, 353t
subacute, 25e–3f, 2128
telangiectasias, 356t, 357
treatment of, 2132, 2134
vasculitis, 363, 2193
gastrointestinal, 2129t, 2131
hematologic, 664, 2129t, 2131
hemoptysis, 245
lymphadenopathy, 408
musculoskeletal, 2127, 2129t
neurologic, 909t, 2128–2129, 2129t, 2623, 2656, 2683
ocular, 2129t, 2131
oral, 237
pulmonary, 1714, 2129, 2129t
Raynaud's phenomenon, 1649
renal, 1858. *See also* Lupus nephritis
splenomegaly, 411
systemic, 2127, 2129t
course of, 2131
definition of, 2124
diagnosis of, 2126–2127, 2127t, 2131, 2328f
drug-induced, 379, 2134
EBV and, 2126
environmental factors in, 2125f, 2126
epidemiology of, 2124
genetic considerations in, 373e–8t, 2125–2126, 2125f
global considerations in, 2134
HLA gene association with, 373e–8t
incidence and prevalence of, 2124
inflammatory mediators in, 372e–29t
microvascular thrombotic crisis in, 2133–2134
pathogenesis of, 2124–2126, 2125f, 2126t
pathoimmunology of, 372e–24–25t, 372e–27t, 377e–2
pathology of, 2124–2126, 2125f, 2126
prognosis of, 2134
sex-related factors in, 2125–2126
survival rates, 2134
treatment of, 2128f, **2131**
cytokine blockers, 377e–5
experimental therapies, 2134
life-threatening disease, 2132–2133
non-life-threatening disease, 2132
outcomes, 2134
pharmacologic, 2130t, 2132–2134
during pregnancy, 2133
for prevention of complications, 2134
special conditions, 2133–2134
- Systemic lytic state, 758
- Systemic mastocytosis. *See* Mastocytosis, systemic
- Systemic mastocytosis associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD), 2120, 2120t
- Systemic necrotizing vasculitis, 372e–8
- Systemic onset juvenile idiopathic arthritis (SOJIA), 372e–8t
- Systemic sclerosis (scleroderma), **2154**
cancer associated with, 2162–2163
clinical features of, 2158, 2158t
acro-osteolysis, 2160, 2160f
cardiac, 1471, 1471t, 1567, 2158, 2162
cutaneous, **375**, 2159–2160
calcinosis, 376, 2160, 2160f
vs. dermatomyositis, 375
digital necrosis, 376f, 2159f
dystrophic calcification, 363
facial, 76e–14f, 376f
hyperpigmentation, 360, 360t
hypopigmentation, 357t, 359
limited vs. diffuse, 2155t
pathology of, 2157, 2157f
sclerodactyly, 2159f
telangiectasias, 356t, 357, 376, 2160f
vascular, 2160, 2160f
esophageal involvement/dysphagia, 256, 257, 1911
facial hemiatrophy, 2649
gastrointestinal, 259, 2158, 2161–2162, 2164
initial presentation, 2159
musculoskeletal, 2162, 2218t
neuropathy, 2683
ocular, 2162
pulmonary
interstitial lung disease, 1713, 2160–2161, 2161f
pathology of, 2157–2158, 2158f
pulmonary arterial hypertension, 1658, 2161, 2164
Raynaud's phenomenon, 1649, 2156, 2159, 2159f, 2160f
renal, 62e–9f, 1864–1865, 2158, 2162, 2164
vasculopathy, 2156, 2162
definition of, 2154
diagnosis of, 2163
diffuse cutaneous, 2155t
environmental factors in, 2155
epidemiology of, 2155
genetic considerations in, 2155
limited cutaneous, 2155t
linear, 376
localized, 2165
natural history of, 2165
pathogenesis of, 372e–15t, 372e–24–25t, 2156–2157, 2157t
pathology of, 2157–2158, 2158f
pregnancy in, 2162
prognosis of, 2165
risk factors for, 2155–2156
treatment of, **2163**
antifibrotic therapy, 2164
for gastrointestinal complications, 2164
immunosuppressive agents, 2163–2164
for musculoskeletal complications, 2165
principles of, 2163, 2163t
for pulmonary complications, 1713, 2164